MannKind (NASDAQ:MNKD) Announces Earnings Results

MannKind (NASDAQ:MNKD) announced its quarterly earnings results on Thursday. The biopharmaceutical company reported ($0.01) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.06) by $0.05, FiscalAI reports. The business had revenue of $101.87 million for the quarter, compared to analyst estimates of $107.74 million. MannKind’s quarterly revenue was up 24.0% compared to the same quarter last year. During the same period last year, the firm earned $0.03 EPS.

Here are the key takeaways from MannKind’s conference call:

• Revenue growth broadened beyond collaborations: Third-quarter revenue rose 24% to $101.9 million, with commercial product revenue roughly doubling to $45 million. Tyvaso DPI royalties increased 12% to $37.5 million, while MannKind said its United Therapeutics agreement is expected to provide more than $1 billion in revenue from 2027 through 2030.
• FUROSCIX ReadyFlow adoption is moving quickly: About 75% of shipments had shifted to ReadyFlow by late October, and the company expects fourth-quarter FUROSCIX sales to roughly match first-half 2026 sales. ReadyFlow’s lower cost of goods could also improve margins as the transition progresses.
• Afrezza’s pediatric launch is gaining traction, but the adult business has underperformed: Pediatric patients now account for about one in four prescriptions, and new-to-brand prescriptions rose nearly 80% sequentially. Management attributed adult weakness partly to reduced promotional support and field-team turnover, and said it plans to refocus resources.
• Management expects a return to profitability: Despite a third-quarter GAAP net loss of $23.2 million, the company expects GAAP and non-GAAP profitability in the fourth quarter and annual profitability in 2027, while continuing to invest in commercial growth.
• Nintedanib DPI advanced, with a longer-term clinical milestone ahead: MannKind reported positive Phase I-B safety and tolerability results and is starting its streamlined Phase II study, with a readout expected in the first half of 2028. The timeline could move faster if the FDA supports adding U.S. sites.

MannKind Price Performance

MannKind stock traded up $0.14 during trading hours on Friday, hitting $3.90. The company had a trading volume of 4,984,958 shares, compared to its average volume of 3,481,324. The firm has a market cap of $1.25 billion, a PE ratio of -16.96 and a beta of 1.10. MannKind has a one year low of $2.23 and a one year high of $6.51. The firm has a 50-day moving average of $3.55 and a 200 day moving average of $3.71.

Key MannKind News

Here are the key news stories impacting MannKind this week:

• Positive Sentiment: Analysts raised price targets. Cantor Fitzgerald lifted its target to $10 from $8 and maintained an “overweight” rating. RBC raised its target to $5 from $4.75, while keeping a “sector perform” rating. Cantor Fitzgerald analyst information RBC price target report
• Positive Sentiment: Longer-term revenue and profitability outlook. MannKind expects its United Therapeutics agreement to generate about $1 billion in revenue from 2027 through 2030, and is targeting profitability in the fourth quarter. United Therapeutics deal and profitability outlook
• Neutral Sentiment: Quarterly results were mixed. MannKind’s revenue rose 24% year over year to $101.87 million, and its reported loss per share was narrower than the consensus estimate. MannKind third-quarter results
• Negative Sentiment: Revenue missed expectations, and the company remained loss-making. Sales of $101.87 million were below analysts’ $107.74 million estimate, while EPS was down from a profit in the year-ago quarter. Q3 loss and revenue miss

Wall Street Analysts Forecast Growth

MNKD has been the subject of several research analyst reports. Cantor Fitzgerald lifted their target price on MannKind from $8.00 to $10.00 and gave the stock an “overweight” rating in a research note on Friday. Wall Street Zen upgraded MannKind from a “sell” rating to a “hold” rating in a research note on Saturday. Zacks Research upgraded MannKind from a “strong sell” rating to a “hold” rating in a research note on Monday, October 5th. Chardan Capital initiated coverage on MannKind in a report on Monday, October 19th. They set a “buy” rating and a $10.00 price target for the company. Finally, Royal Bank Of Canada raised their price target on MannKind from $4.75 to $5.00 and gave the company a “sector perform” rating in a report on Friday. Eight research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, MannKind currently has an average rating of “Moderate Buy” and an average target price of $8.33.

Insider Activity

In other news, Director Steven Binder sold 39,051 shares of the business’s stock in a transaction that occurred on Friday, September 25th. The stock was sold at an average price of $3.29, for a total transaction of $128,477.79. Following the completion of the sale, the director owned 713,258 shares in the company, valued at $2,346,618.82. The trade was a 5.19% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. 2.60% of the stock is currently owned by corporate insiders.

About MannKind

MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes, and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults. The company's product pipeline also includes Tyvaso DPI (Treprostinil), an inhalation powder for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease; MNKD-101, a nebulized formulation of clofazimine, for the treatment of severe chronic and recurrent pulmonary infections, including nontuberculous mycobacterial lung disease; MNKD-201, a dry-powder formulation of nintedanib, for the treatment of idiopathic pulmonary fibrosis (IPF).